分子量:70.2 kDa

纯度:>92% as determined by SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the Human Osteoprotegerin, Fc Tag by the LAL method.

Buffer:50 mM tris, 100 mM glycine, pH7.5

生物活性:Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 16 - 32 ng/mL in the presence of 10 ng/mL recombinant human TRAIL.

产品特性:Human Osteoprotegerin, Fc Tag is fused with a human IgG1 Fc tag at the C-terminus, and has a calculated MW of 70.2 kDa. The predicted N-terminus is Glu 22. As a result of glycosylation, the reducing (R) protein migrates as 66-85 kDa, and the non-reducing (NR) protein migrates as 130-170 kDa in SDS-PAGE .

产品背景:Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) is also known as Osteoclastogenesis inhibitory factor (OCIF), Osteoprotegerin (OPG). TNFRSF11B is a secreted homodimer protein, which can interact with TNFSF10 and TNFSF11. TNFRSF11B acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. TNFRSF11B inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.